The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.
David Raymond Ferry
Consultant or Advisory Role - Regeneron; Sanofi
Honoraria - Regeneron; Sanofi
Tae Won Kim
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Jayesh Desai
Consultant or Advisory Role - Sanofi
Luis Marcelo Villanueva
No relevant relationships to disclose
Michael L. Andria
Employment or Leadership Position - Regeneron
Eric Van Cutsem
Research Funding - Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx; Pfizer; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi